Sanofi Profit Growth Beats Market View on Early Start of Vaccine Sales
Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...
Sanofi Profit, Sales Beat Estimates
Sales rose 12% to 13.44 billion euros on the continued strength of its anti-inflammatory drug Dupixent and sales in its pharma segment, which offset currency headwinds. Analysts expected business ...
Sanofi Q3 earnings beat market view, boosted by vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...
Sanofi’s Strategic Moves and Financial Prospects Drive Buy Rating
Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...
BioSpace3d
Sanofi Seals Deal With Private Equity Firm for 50% Stake in Consumer Healthcare Unit
Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...
FiercePharma3d
Sanofi in 'exclusive negotiations' to sell 50% stake in €16B consumer health unit Opella
Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...
Jefferies Sticks to Their Buy Rating for Sanofi (SNYNF)
In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target ...